CLVS on NASDAQ

Clovis Oncology

American pharmaceutical company

Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

2009Founded1

Compare with ELITE PHARMACEUTICALS INC /NV/, MACROGENICS INC or Karyopharm Therapeutics Inc., or pick any stock.

  • TickerCLVS on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersWilmington1
  • Websiteclovisoncology.com
  • Legal formpublic company1
  • Incorporated inDE5
  • Business address5500 Flatiron Parkway, Suite 100, Boulder, Co 803015
  • Filer categoryLarge accelerated filer5
  • LEI529900WCUY9ZAHMRV4894
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 46783604

See how the biggest companies compare on our leaderboards

Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for Chapter 11 bankruptcy.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-151.8%Operating margin7
-177.8%Net margin7
-9.6%Revenue growth, 20217
-$196.4MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Selling, general and admin86¢$128.4M
  • Other costs13¢$20.0M
  • Income tax0¢$404.0K

Out of $148.8M in revenue.7 The company lost money this year.

Financial statements

Revenue8910117$148.8M in 2021
0$50.0M$100.0M$150.0M$200.0M2015: $0$020152016: $78.0K$78.0K20162017: $55.5M$55.5M2017+71068%2018: $95.4M$95.4M2018+72%2019: $143.0M$143.0M2019+50%2020: $164.5M$164.5M2020+15%2021: $148.8M$148.8M2021−10%
Operating income12910117-$225.8M in 2021−40% since 2015
-$400.0M-$300.0M-$200.0M-$100.0M02015: -$376.7M-$376.7M20152016: -$372.7M-$372.7M2016−1%2017: -$237.6M-$237.6M2017−36%2018: -$333.8M-$333.8M2018+40%2019: -$376.7M-$376.7M2019+13%2020: -$302.2M-$302.2M2020−20%2021: -$225.8M-$225.8M2021−25%
Net income12910117-$264.5M in 2021−25% since 2015
-$600.0M-$400.0M-$200.0M02015: -$352.9M-$352.9M20152016: -$349.1M-$349.1M2016−1%2017: -$346.4M-$346.4M2017−1%2018: -$368.0M-$368.0M2018+6%2019: -$400.4M-$400.4M2019+9%2020: -$369.2M-$369.2M2020−8%2021: -$264.5M-$264.5M2021−28%
Fiscal year2015201620172018201920202021
Revenue$08$78.0K9$55.5M10$95.4M11$143.0M7$164.5M7$148.8M7
Cost of revenue$08$70.0K8
Selling, general and admin$30.5M12$40.7M9$138.9M10$175.8M11$182.8M7$163.9M7$128.4M7
Operating expenses$374.5M7
Operating income-$376.7M12-$372.7M9-$237.6M10-$333.8M11-$376.7M7-$302.2M7-$225.8M7
Interest
Income before tax-$264.9M7
Income tax-$29.1M12-$32.0M9-$3.6M10$608.0K11$1.8M7-$547.0K7-$404.0K7
Net income-$352.9M12-$349.1M9-$346.4M10-$368.0M11-$400.4M7-$369.2M7-$264.5M7
Earnings per share-$7.437-$4.387-$2.297
Earnings per share (diluted)-$7.437-$4.387-$2.297
Shares (weighted, basic)115.5M shares7
Shares (weighted, diluted)115.5M shares7

Compare Clovis Oncology with another company

The story

Clovis Oncology was founded in 2009 by Patrick Mahaffy in Boulder, Colorado. The company was named in honor of the Mahaffy cache, a collection of Clovis period stone tools dated to 11,000 BCE, discovered in the front yard of Mahaffy's home in Boulder.

From Wikipedia’s article on Clovis Oncology, shared under CC BY-SA 4.0.6

Leadership

Who has led Clovis Oncology, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Patrick J. Mahaffy2011–2020

President

  1. Patrick J. Mahaffy2011–2020

Chief financial officer

  1. Erle T. Mast2011–2015
2010201520202025
Board members and other officers (22)

Products and brands

Rociletinib

The company was developing rociletinib, as a treatment for non-small cell lung cancer. A phase III trial was completed in April 2016 and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib). According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment.

In September 2018, the company and two former executives agreed to a $20 million settlement with the Securities and Exchange Commission on claims it exaggerated to investors the efficacy of Roci in patient trials.

Rucaparib

Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer. In December 2016, the Food and Drug Administration granted an accelerated approval for the use of rucaparib "for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies". In 2023, rucaparib was sold to Pharmaand GmbH (Pharma&) as part of Clovis's bankruptcy proceedings.

Lucitanib

Lucitanib is a VEGFR inhibitor. It is also an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors.

From Wikipedia’s article on Clovis Oncology, shared under CC BY-SA 4.0.6

Timeline

  1. Nov 16, 2011Went public Listed on NASDAQ1
  2. Nov 15, 2011New chief executive Patrick J. Mahaffy becomes CEO15
  3. 2009Founded Founded1

Filings

111 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 27 major events, 51 insider forms, 7 large holders, 21 other. The latest 20:

  1. Jul 17, 2023EFFECT EDGAR
  2. Jul 11, 202315-12G EDGAR
  3. Jul 11, 2023S-8 POS EDGAR
  4. Jul 11, 2023S-8 POS EDGAR
  5. Jul 11, 2023S-8 POS EDGAR
  6. Jul 11, 2023S-8 POS EDGAR
  7. Jul 11, 2023S-8 POS EDGAR
  8. Jul 11, 2023S-8 POS EDGAR
  9. Jul 11, 2023S-8 POS EDGAR
  10. Jul 11, 2023S-8 POS EDGAR
  11. Jul 11, 2023S-8 POS EDGAR
  12. Jul 11, 2023S-8 POS EDGAR
  13. Jul 11, 2023S-8 POS EDGAR
  14. Jul 11, 2023POS AM EDGAR
  15. Jul 11, 20238-K EDGAR
  16. Jun 30, 20238-K EDGAR
  17. Jun 2, 20238-K EDGAR
  18. May 3, 20238-K EDGAR
  19. May 1, 20238-K EDGAR
  20. Apr 14, 20238-K EDGAR

The 111 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 0 buys and 50 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 2, 2022Gross Paul EdwardSee RemarksSale4,730$0.98$4.6KForm 4
Nov 2, 2022IVERS-READ GILLIAN CSee RemarksSale3,681$0.98$3.6KForm 4
Nov 2, 2022Harding Thomas C.See RemarksSale1,766$0.98$1.7KForm 4
Nov 2, 2022MUEHL DANIEL WSee RemarksSale4,579$0.98$4.5KForm 4
Nov 2, 2022Rolfe LindseySee RemarksSale4,261$0.98$4.2KForm 4
Oct 3, 2022Harding Thomas C.See RemarksSale6$1.29$8Form 4
Sep 2, 2022Rolfe LindseySee RemarksSale2,545$1.20$3.1KForm 4
Sep 2, 2022Gross Paul EdwardSee RemarksSale2,308$1.20$2.8KForm 4
Sep 2, 2022Harding Thomas C.See RemarksSale1,616$1.20$1.9KForm 4
Sep 2, 2022IVERS-READ GILLIAN CSee RemarksSale2,234$1.20$2.7KForm 4
Sep 2, 2022MUEHL DANIEL WSee RemarksSale2,234$1.20$2.7KForm 4
Aug 2, 2022MUEHL DANIEL WSee RemarksSale4,654$1.46$6.8KForm 4
Aug 2, 2022Rolfe LindseySee RemarksSale4,330$1.46$6.3KForm 4
Aug 2, 2022IVERS-READ GILLIAN CSee RemarksSale3,802$1.46$5.6KForm 4
Aug 2, 2022Gross Paul EdwardSee RemarksSale4,807$1.46$7.0KForm 4
Aug 2, 2022Harding Thomas C.See RemarksSale1,809$1.46$2.6KForm 4
Jul 5, 2022Harding Thomas C.See RemarksSale7$2.71$19Form 4
Jun 2, 2022Harding Thomas C.See RemarksSale1,722$0.64$1.1KForm 4
Jun 2, 2022MUEHL DANIEL WSee RemarksSale2,327$0.64$1.5KForm 4
Jun 2, 2022Rolfe LindseySee RemarksSale2,650$0.64$1.7KForm 4

All 50 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41